Pharmacology Quiz: Targeted Therapy And Monoclonals

20 questions · exam conditions

0:00

Targeted Therapy And MonoclonalsQuestion 1 of 20

A patient with newly diagnosed metastatic non-small cell lung cancer (NSCLC) undergoes molecular testing. The results are positive for an EML4-ALK gene rearrangement but negative for EGFR and BRAF mutations. Which of the following targeted therapies is the most appropriate first-line choice?

Osimertinib

Dabrafenib

Alectinib

Trastuzumab

← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Targeted Therapy And Monoclonals

Practice Targeted Therapy And Monoclonals in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Targeted Therapy And Monoclonals, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Osimertinib
Dabrafenib
Alectinib (correct answer)
Trastuzumab

Explanation: The presence of an EML4-ALK gene rearrangement identifies a specific subset of NSCLC that is driven by the constitutively active ALK fusion protein. Alectinib is a highly potent, second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is a standard first-line treatment for ALK-positive NSCLC.

Question 2

A patient with relapsed follicular lymphoma is receiving their first infusion of rituximab. The nurse practitioner ensures that an appropriate premedication regimen is administered. What is the primary rationale for premedicating with acetaminophen, diphenhydramine, and a corticosteroid before the initial rituximab infusion?

To mitigate the risk of a cytokine-release-mediated infusion reaction from rapid B-cell lysis. (correct answer)
To prevent tumor lysis syndrome by reducing the initial cytotoxic effect on B-cells.
To reduce the likelihood of a Type I IgE-mediated anaphylactic reaction to the chimeric antibody.
To prevent delayed nausea and vomiting commonly associated with anti-CD20 therapy.

Explanation: When you encounter questions about monoclonal antibody premedication, focus on the mechanism of action and timing of potential adverse effects. Rituximab is an anti-CD20 monoclonal antibody that binds to CD20 receptors on B-cells, leading to rapid cell destruction and cytokine release. The correct answer is A because rituximab causes immediate B-cell lysis upon binding, which triggers the release of inflammatory cytokines like TNF-α, IL-6, and histamine. This cytokine release syndrome typically occurs within the first few hours of infusion and manifests as fever, chills, rigors, hypotension, and bronchospasm. The premedication triad works synergistically: acetaminophen reduces fever, diphenhydramine blocks histamine receptors, and corticosteroids suppress the overall inflammatory cascade. Option B is incorrect because tumor lysis syndrome involves metabolic disturbances (hyperkalemia, hyperphosphatemia, hyperuricemia) from massive cell death, which occurs hours to days later and isn't prevented by these premedications. Option C misidentifies the mechanism—this isn't a true IgE-mediated allergic reaction but rather a predictable cytokine-mediated response that occurs in most patients. Option D is wrong because rituximab rarely causes significant nausea/vomiting compared to traditional chemotherapy, and the premedications listed aren't standard antiemetics. Remember that monoclonal antibodies like rituximab have predictable, dose-dependent infusion reactions due to their mechanism of action, not unpredictable allergic reactions. Always associate anti-CD20 therapy with cytokine release syndrome requiring prophylactic premedication before the first infusion.

Question 3

A patient receiving axicabtagene ciloleucel (a CD19-directed CAR-T cell therapy) for relapsed lymphoma develops a fever of 39.5°C, tachycardia, hypotension requiring vasopressors, and hypoxemia within 36 hours of the infusion. Laboratory workup shows markedly elevated levels of C-reactive protein, ferritin, and interleukin-6.

This clinical syndrome is best described as which of the following?

Tumor Lysis Syndrome (TLS)
Anaphylaxis to the cryopreservative
Graft-versus-Host Disease (GVHD)
Cytokine Release Syndrome (CRS) (correct answer)

Explanation: When you encounter a question about CAR-T cell therapy complications, focus on the timeline and clinical presentation to distinguish between the major adverse effects. CAR-T cells are engineered to rapidly activate and proliferate when they encounter their target antigen, which can trigger massive immune system activation. The correct answer is (D) Cytokine Release Syndrome (CRS). This patient's presentation is classic for CRS: fever, cardiovascular instability (tachycardia, hypotension requiring vasopressors), respiratory compromise (hypoxemia), and the hallmark laboratory findings of elevated inflammatory markers (CRP, ferritin, and especially IL-6). CRS typically occurs within hours to days after CAR-T infusion as the engineered T cells encounter tumor cells and release massive amounts of inflammatory cytokines. (A) Tumor Lysis Syndrome would present with metabolic derangements like hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia, not the inflammatory profile seen here. (B) Anaphylaxis occurs within minutes of infusion and involves histamine-mediated symptoms like urticaria, bronchospasm, and angioedema, plus it wouldn't cause these specific lab abnormalities. (C) Graft-versus-Host Disease is not relevant here since CAR-T cells are autologous (the patient's own modified T cells), and GVHD typically affects skin, GI tract, and liver with a different timeline. Study tip: For CAR-T therapy questions, remember the "Big 2" complications: CRS (systemic inflammatory response with IL-6 elevation) and neurotoxicity (confusion, seizures). The inflammatory markers, especially IL-6, are your key clue for CRS.

Question 4

Denosumab and zoledronic acid are both used to prevent skeletal-related events in patients with bone metastases, but they have distinct mechanisms of action. The mechanism of denosumab involves which of the following?

Binding to hydroxyapatite crystals in bone and being internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase.
Chelating free calcium in the bone microenvironment, which serves as a signal to halt osteoclast-mediated resorption.
Directly inducing apoptosis in osteoblasts, thereby shifting the bone remodeling balance away from resorption.
Functioning as a monoclonal antibody that binds to and neutralizes RANKL, preventing osteoclast differentiation and activation. (correct answer)

Explanation: When you encounter questions about bone-protective agents, focus on their distinct mechanisms of action. Both denosumab and zoledronic acid prevent skeletal-related events, but they work through completely different pathways in bone remodeling. Denosumab is a human monoclonal antibody that specifically targets RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). RANKL is a crucial signaling protein that normally binds to RANK receptors on osteoclast precursors, triggering their differentiation into mature, bone-resorbing osteoclasts. By binding to and neutralizing RANKL, denosumab effectively blocks this signal, preventing osteoclast formation and activation. This makes option D correct. Option A describes the mechanism of bisphosphonates like zoledronic acid, not denosumab. Bisphosphonates bind to hydroxyapatite in bone matrix and are internalized by osteoclasts, where they inhibit farnesyl pyrophosphate synthase, ultimately causing osteoclast apoptosis. Option B is incorrect because denosumab doesn't work by chelating calcium. Calcium chelation would be more characteristic of certain other therapeutic approaches. Option C is wrong because denosumab doesn't target osteoblasts at all. It specifically affects the osteoclast pathway through RANKL inhibition, and inducing osteoblast apoptosis would actually be counterproductive for bone protection. Remember this key distinction: bisphosphonates work by being incorporated into bone and poisoning osteoclasts from within, while denosumab works by blocking the external signals that create osteoclasts in the first place. This fundamental difference explains their different dosing schedules and side effect profiles.

Question 5

A patient with metastatic triple-negative breast cancer is treated with sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2. The patient develops Grade 4 neutropenia and severe, late-onset diarrhea.

These specific adverse events are most directly attributable to the systemic effects of which component of the drug?

The anti-Trop-2 monoclonal antibody (sacituzumab).
The cleavable linker molecule prior to hydrolysis.
The topoisomerase I inhibitor payload (SN-38). (correct answer)
Fc-gamma receptor binding on myeloid cells.

Explanation: Sacituzumab govitecan's payload is govitecan, which is a derivative of SN-38, the active metabolite of irinotecan. SN-38 is a potent topoisomerase I inhibitor. The classic, dose-limiting toxicities of irinotecan (and thus SN-38) are severe myelosuppression (especially neutropenia) and severe diarrhea. These toxicities occur when the payload is released from the conjugate and exerts its effect on rapidly dividing cells, such as hematopoietic progenitors and gastrointestinal epithelial cells.

Question 6

A patient with castration-resistant prostate cancer and known bone metastases is found to have a somatic mutation in BRCA2. The oncologist is considering initiating a targeted therapy.

Which of the following agents is most appropriate to consider for this patient based on the identified mutation?

Rucaparib (correct answer)
Sipuleucel-T
Abiraterone acetate
Radium-223

Explanation: When you encounter a question about targeted therapy for cancer with a specific genetic mutation, you need to match the mutation to the drug mechanism that exploits that particular vulnerability. BRCA2 mutations create a critical weakness in DNA repair pathways. BRCA2 normally helps repair double-strand DNA breaks through homologous recombination. When this gene is mutated, cancer cells become heavily dependent on an alternative repair mechanism called base excision repair, which relies on the enzyme PARP (poly ADP-ribose polymerase). This creates a therapeutic opportunity called "synthetic lethality" - blocking PARP in BRCA-mutated cells causes catastrophic DNA damage and cell death. Rucaparib (A) is a PARP inhibitor that exploits exactly this vulnerability. By blocking PARP in BRCA2-mutated prostate cancer cells, it creates lethal DNA damage accumulation, making it the ideal targeted therapy for this patient's specific mutation. The other options don't target the BRCA2 defect. Sipuleucel-T (B) is an immunotherapy vaccine that stimulates T-cells against prostate acid phosphatase - it's not mutation-specific. Abiraterone acetate (C) blocks androgen synthesis by inhibiting CYP17A1, targeting hormone-sensitive pathways rather than DNA repair defects. Radium-223 (D) is a radiopharmaceutical that targets bone metastases through alpha radiation but doesn't exploit genetic vulnerabilities. Remember this key principle: when you see BRCA mutations (BRCA1 or BRCA2) in any cancer type, think PARP inhibitors. This synthetic lethality concept is increasingly tested as precision oncology becomes more prominent in clinical practice.

Question 7

A 58-year-old patient with metastatic non-small cell lung cancer (NSCLC) is found to have an EGFR exon 19 deletion. The patient is started on first-line therapy with gefitinib and has a good partial response for 14 months. However, recent imaging shows disease progression. A liquid biopsy is performed and reveals the emergence of a T790M mutation in addition to the original exon 19 deletion.

Based on these new molecular findings, which of the following is the most appropriate next line of therapy for this patient?

Alectinib
Crizotinib
Osimertinib (correct answer)
Pembrolizumab

Explanation: The patient has developed a T790M resistance mutation to a first-generation EGFR tyrosine kinase inhibitor (TKI), gefitinib. Osimertinib is a third-generation EGFR TKI specifically designed to be effective against tumors with the T790M resistance mutation, while also targeting the initial sensitizing EGFR mutations (like exon 19 deletion).

Question 8

A new monoclonal antibody, "Tusiximab," is being developed. Based on international nonproprietary name (INN) conventions for monoclonal antibodies, what can be inferred about this agent's composition and its likely degree of immunogenicity compared to a humanized antibody?

It is a chimeric antibody, likely possessing a higher potential for immunogenicity than a humanized (-zumab) antibody. (correct answer)
It is a humanized antibody, likely possessing a lower potential for immunogenicity than a fully human (-umab) antibody.
It is a fully human antibody, indicating it will have no potential for immunogenicity compared to a chimeric (-ximab) antibody.
It is a murine antibody, indicating it targets the tumor stroma (-six-) and is less immunogenic than a humanized antibody.

Explanation: The suffix "-ximab" indicates a chimeric monoclonal antibody, which contains a murine variable region (~25-30%) and a human constant region. Because they contain a significant portion of non-human protein, chimeric antibodies are more immunogenic than humanized antibodies (suffix "-zumab"), which contain only the murine complementarity-determining regions (~5-10%).

Question 9

A patient with BRAF V600E-mutant metastatic melanoma is treated with dabrafenib, a BRAF inhibitor. After several months, the patient develops multiple cutaneous squamous cell carcinomas and keratoacanthomas on sun-exposed skin.

This dermatologic toxicity is thought to be caused by paradoxical activation of the MAPK pathway in BRAF wild-type cells. The addition of which of the following agents is most likely to mitigate this specific adverse effect while also improving anti-tumor efficacy?

Ipilimumab
Bevacizumab
Vemurafenib
Trametinib (correct answer)

Explanation: When you encounter questions about targeted cancer therapy side effects, focus on understanding the underlying pathway mechanisms and how combination therapies can address resistance or toxicity issues. The key insight here is understanding BRAF inhibitor paradoxical activation. In BRAF wild-type cells (like normal skin cells), BRAF inhibitors can actually activate the MAPK pathway instead of inhibiting it. This occurs because the inhibitor causes BRAF to form dimers that enhance downstream signaling, leading to hyperproliferation and the cutaneous malignancies described. Trametinib (D) is the correct answer because it's a MEK inhibitor that works downstream of BRAF in the MAPK pathway. By blocking MEK, trametinib prevents the paradoxical MAPK activation in wild-type cells, reducing skin toxicity. Additionally, the BRAF/MEK inhibitor combination shows superior anti-tumor efficacy in BRAF-mutant melanomas compared to BRAF inhibition alone, as it provides more complete pathway blockade. Why the other options fail: Ipilimumab (A) is an anti-CTLA-4 immunotherapy that doesn't address MAPK pathway activation. Bevacizumab (B) is an anti-VEGF agent targeting angiogenesis, not relevant to this mechanism. Vemurafenib (C) is another BRAF inhibitor that would likely worsen the paradoxical activation problem rather than solve it. Study tip: Remember that combination targeted therapies often serve dual purposes - overcoming resistance mechanisms while reducing toxicity. BRAF + MEK inhibitor combinations are standard care for BRAF-mutant melanoma specifically because they address the paradoxical activation problem inherent to BRAF inhibitor monotherapy.

Question 10

Cetuximab, a monoclonal antibody, and gefitinib, a small molecule tyrosine kinase inhibitor, both inhibit the epidermal growth factor receptor (EGFR) signaling pathway. Which of the following represents a fundamental difference in their mechanism of action?

Cetuximab binds to the intracellular tyrosine kinase domain, while gefitinib binds to the extracellular ligand-binding domain.
Cetuximab prevents ligand binding to the extracellular domain, while gefitinib inhibits the intracellular kinase phosphorylation cascade. (correct answer)
Gefitinib is only effective against wild-type EGFR, while cetuximab is effective against both wild-type and mutated EGFR.
Gefitinib's activity is dependent on an intact immune system for ADCC, while cetuximab directly induces apoptosis.

Explanation: The primary difference lies in their binding sites and direct mechanism. Cetuximab is a large protein (monoclonal antibody) that binds to the extracellular domain of EGFR, physically blocking the binding of ligands like EGF and TGF-α. Gefitinib is a small molecule that can diffuse across the cell membrane and binds to the ATP-binding site of the intracellular tyrosine kinase domain, preventing autophosphorylation and activation of downstream signaling.

Question 11

Blinatumomab is a bi-specific T-cell engager (BiTE) antibody construct used in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Which statement most accurately describes its mechanism of action?

It cross-links tumor cells via CD19 and natural killer (NK) cells via their Fc receptors, inducing antibody-dependent cell-mediated cytotoxicity (ADCC).
It binds to the CD19 antigen on malignant B-cells and the CD3 complex on T-cells, forcing a synapse that triggers T-cell-mediated lysis of the tumor cell. (correct answer)
It functions as a checkpoint inhibitor by binding to PD-L1 on B-cells and PD-1 on T-cells, thereby restoring the T-cell's intrinsic anti-tumor activity.
It directly induces apoptosis in malignant B-cells by agonizing the Fas receptor (CD95) while simultaneously providing a co-stimulatory signal to nearby T-cells.

Explanation: Blinatumomab is a BiTE, a construct with two different single-chain variable fragments. One end binds to CD19, an antigen expressed on the surface of B-cells (including malignant ones), and the other end binds to CD3, a component of the T-cell receptor complex. This physical linkage creates an artificial synapse, leading to T-cell activation and potent, targeted killing of the B-cell, independent of T-cell receptor specificity.

Question 12

A patient with chronic myeloid leukemia (CML) has been well-controlled on imatinib for three years. However, recent bloodwork shows a rising white blood cell count and an increased percentage of BCR-ABL1 transcripts. Genetic sequencing of the ABL kinase domain is performed.

The sequencing reveals a T315I mutation. Which of the following therapeutic adjustments is most appropriate?

Increase the dose of imatinib to overcome competitive inhibition.
Switch to dasatinib or nilotinib to target the mutated kinase.
Switch to ponatinib, a third-generation tyrosine kinase inhibitor. (correct answer)
Add rituximab to target any co-expression of CD20 on leukemic cells.

Explanation: The T315I mutation is known as the "gatekeeper" mutation in the ABL kinase domain. It confers resistance to imatinib as well as second-generation TKIs like dasatinib and nilotinib by sterically hindering drug binding. Ponatinib is a third-generation TKI specifically designed to be effective against BCR-ABL harboring the T315I mutation.

Question 13

A patient with HER2-positive breast cancer is being treated with trastuzumab emtansine (T-DM1), an antibody-drug conjugate. A known risk of this therapy is cardiotoxicity. Which component of T-DM1 is primarily responsible for this specific adverse effect?

The emtansine (DM1) payload, via disruption of microtubule function in cardiomyocytes.
The trastuzumab component, via interference with HER2 signaling pathways in cardiac cells. (correct answer)
The non-cleavable thioether linker, by causing direct membrane damage to cardiac myocytes.
A host immune response against the entire conjugate, leading to complement-mediated cardiotoxicity.

Explanation: Cardiotoxicity is a well-established adverse effect of trastuzumab itself. The HER2 receptor is expressed on cardiomyocytes and is believed to play a role in their survival and response to stress. Inhibition of this pathway by trastuzumab is the primary mechanism of cardiotoxicity. While the emtansine payload has its own toxicities, the cardiotoxicity is attributed to the antibody portion.

Question 14

A 45-year-old patient with metastatic melanoma is receiving treatment with ipilimumab and nivolumab. Several weeks into therapy, the patient presents with severe, watery diarrhea, abdominal cramping, and is subsequently diagnosed with grade 3 colitis. The patient also complains of profound fatigue and is found to have a TSH of 15 mU/L (normal 0.4-4.0 mU/L).

The development of both colitis and hypothyroidism in this patient is most likely a consequence of which mechanism?

Direct cytotoxic effect of the antibodies on gastrointestinal and thyroid follicular cells.
Global T-cell activation leading to a break in self-tolerance and autoimmune-like organ damage. (correct answer)
Inhibition of a tyrosine kinase pathway essential for normal gut and thyroid homeostasis.
A delayed-type hypersensitivity reaction specifically targeting shared antigens in the colon and thyroid.

Explanation: Ipilimumab (an anti-CTLA-4 antibody) and nivolumab (an anti-PD-1 antibody) are immune checkpoint inhibitors. Their mechanism involves blocking inhibitory signals on T-cells, leading to a general enhancement of T-cell activity. This can cause a break in self-tolerance, where activated T-cells attack normal host tissues, resulting in a spectrum of immune-related adverse events (irAEs), such as colitis and endocrinopathies like hypothyroidism.

Question 15

It is a chimeric antibody, likely possessing a higher potential for immunogenicity than a humanized (-zumab) antibody. (correct answer)
It is a humanized antibody, likely possessing a lower potential for immunogenicity than a fully human (-umab) antibody.
It is a fully human antibody, indicating it will have no potential for immunogenicity compared to a chimeric (-ximab) antibody.
It is a murine antibody, indicating it targets the tumor stroma (-six-) and is less immunogenic than a humanized antibody.

Question 16

A 72-year-old patient with metastatic colorectal cancer is started on a FOLFIRI chemotherapy regimen plus bevacizumab. The patient has a history of well-controlled hypertension managed with a single agent.

Given the addition of bevacizumab, which of the following sets of parameters requires the most vigilant monitoring due to the drug's specific mechanism-related toxicities?

QTc interval and serum potassium levels.
Blood pressure and urine protein levels. (correct answer)
Auditory function and serum creatinine.
Liver function tests and bilirubin levels.

Explanation: Bevacizumab is a monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF). Inhibition of VEGF signaling can disrupt normal vascular homeostasis, leading to characteristic toxicities. The most common and clinically significant of these are hypertension (which can be severe) and proteinuria, which can progress to nephrotic syndrome. Other serious but less common risks include arterial thromboembolism, gastrointestinal perforation, and impaired wound healing.

Question 17

Based on these new molecular findings, which of the following is the most appropriate next line of therapy for this patient?

Alectinib
Crizotinib
Osimertinib (correct answer)
Pembrolizumab

Question 18

The development of both colitis and hypothyroidism in this patient is most likely a consequence of which mechanism?

Direct cytotoxic effect of the antibodies on gastrointestinal and thyroid follicular cells.
Global T-cell activation leading to a break in self-tolerance and autoimmune-like organ damage. (correct answer)
Inhibition of a tyrosine kinase pathway essential for normal gut and thyroid homeostasis.
A delayed-type hypersensitivity reaction specifically targeting shared antigens in the colon and thyroid.

Question 19

The emtansine (DM1) payload, via disruption of microtubule function in cardiomyocytes.
The trastuzumab component, via interference with HER2 signaling pathways in cardiac cells. (correct answer)
The non-cleavable thioether linker, by causing direct membrane damage to cardiac myocytes.
A host immune response against the entire conjugate, leading to complement-mediated cardiotoxicity.

Question 20

The sequencing reveals a T315I mutation. Which of the following therapeutic adjustments is most appropriate?

Increase the dose of imatinib to overcome competitive inhibition.
Switch to dasatinib or nilotinib to target the mutated kinase.
Switch to ponatinib, a third-generation tyrosine kinase inhibitor. (correct answer)
Add rituximab to target any co-expression of CD20 on leukemic cells.